Latest Posts
About This Stock
More About This Stock
Read
GlycoMimetics: A Potential Game Changer In Blood Cancers With Near-Term Catalysts
Article By:
Scott Matusow
Thursday, March 21, 2024 2:25 AM EDT
Glycomimetics' Uproleselan is expected to read out data in relapsed/refractory and elderly newly diagnosed Acute Myeloid Leukemia (AML) after 6 years in pivotal studies.
5 Leading Healthcare Stocks Surging On Pent-up Demand
Just a hunch. The healthcare industry is highly regulated and Dems generally favor more regulation, making it more difficult for drugmakers to secure the necessary regulatory approvals to market new products. Regulatory changes could drastically alter a healthcare stock’s growth prospects, for instance. But I reckon I'll not sell $ABBV after holding during all the long downward spiral.
5 Leading Healthcare Stocks Surging On Pent-up Demand
Seems health stocks should do well but a #Biden presidency will not favor this sector. $ABBV $PFE
Macy’s Q1 Was Bad, But The Company Has The Cash To Survive The Current Pandemic
Glad you liked it Sheryl! Right now I think a range of REITs and healthcare stocks are attractive from a risk-reward standpoint, including $ABBV, $BMY, $O, $SLG, $SPG, etc.
AbbVie: Is This Biopharma Giant’s 6% Yield Safe?
How much debt does $ABBV have?
AbbVie Has It All: Growth, Dividend Growth And Compelling Valuation
$ABBV certainly sounds like a great buy.
AbbVie Inc. Increases Humira Prices, Receives FDA Approval For New Drug
Excited to hear the #FDA approved #IMBRUVICA. Should bode very well for $ABBV. And I think it's 8% price hike of #Humira is reasonable (though I realize those taking the drug may disagree).